The N6-methyladenosine demethylase ALKBH5 is a novel epigenetic regulator of aortic valve calcification

Cardiovasc Res. 2025 Apr 15;121(1):190-204. doi: 10.1093/cvr/cvae253.

Abstract

Aims: Calcific aortic valve disease (CAVD) is a common heart valve disease with significant clinical consequences. The mechanisms that drive the pathogenesis of CAVD remain to be fully elucidated. N6-methyladenosine (m6A), the most prevalent RNA epigenetic regulator, has recently been implicated in cardiovascular disease, but its role in CAVD has yet to be investigated. In this study, we investigated the potential function of m6A modification in CAVD.

Methods and results: Using clinical samples from CAVD patients in combination with human valve interstitial cell (hVIC) calcification model, we screened the expression of m6A modulators and discovered that alkB homolog 5, RNA demethylase (ALKBH5), a key m6A demethylase, was significantly down-regulated in calcified hVICs and human aortic valves. Consistently, increased m6A levels were seen in calcified hVICs, and treatment with 3-deazaadenosine (DAA), an inhibitor of m6A modification, significantly reduced hVIC osteogenic differentiation and calcification. In addition, we showed that silencing of ALKBH5 expression increased global m6A levels and accelerated hVIC osteogenic differentiation and calcification, whereas overexpression of ALKBH5 resulted in the opposite effect. We demonstrated that ALKBH5 directly modulate m6A levels of TGFBR2 and its mRNA stability, leading to altered TGFBR2 expression and SMAD2 signalling in hVICs. We further showed that inhibition of TGFBR2 or knockdown of SMAD2 attenuated ALKBH5 knockdown-induced hVIC osteogenic differentiation and calcification. The expression of the m6A reader protein YTH N6-methyladenosine RNA binding protein F1 (YTHDF1) was up-regulated during the process of hVIC calcification. Intriguingly, we revealed that the ALKBH5 silencing-induced increased hVIC osteogenic differentiation and calcification were abolished after knockdown of YTHDF1. These data suggest a potential role YTHDF1 in aortic valve calcification.

Conclusion: This study showed that ALKBH5 attenuated aortic valve calcification through the TGFBR2/SMAD2 signalling pathway via direct m6A modification of TGFBR2.

Keywords: ALKBH5; Aortic valve calcification; TGFBR2/SMAD2 signalling; m6A modification.

MeSH terms

  • Adenosine* / analogs & derivatives
  • Adenosine* / metabolism
  • Aged
  • AlkB Homolog 5, RNA Demethylase* / genetics
  • AlkB Homolog 5, RNA Demethylase* / metabolism
  • Aortic Valve Stenosis* / enzymology
  • Aortic Valve Stenosis* / genetics
  • Aortic Valve Stenosis* / pathology
  • Aortic Valve* / drug effects
  • Aortic Valve* / enzymology
  • Aortic Valve* / pathology
  • Calcinosis* / enzymology
  • Calcinosis* / genetics
  • Calcinosis* / pathology
  • Cell Differentiation
  • Cells, Cultured
  • Epigenesis, Genetic*
  • Female
  • Heart Valve Diseases* / enzymology
  • Heart Valve Diseases* / genetics
  • Heart Valve Diseases* / pathology
  • Humans
  • Male
  • Middle Aged
  • Osteogenesis
  • Signal Transduction
  • Smad2 Protein / genetics
  • Smad2 Protein / metabolism

Substances

  • AlkB Homolog 5, RNA Demethylase
  • ALKBH5 protein, human
  • Adenosine
  • N-methyladenosine
  • Smad2 Protein

Supplementary concepts

  • Aortic Valve, Calcification of